Ixekizumab  (Synonyms: 伊西贝单抗; LY2439821)

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (K_D<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Ixekizumab 对人和食蟹猴 IL-17A 的平衡 K_D 分别为 1.8 pM 和 0.8 pM。Ixekizumab 也与兔 IL-17A 结合，但亲和力较低，并且结合是异质的 (K_D 为 1.3 nM 和 14 nM)。Ixekizumab 显示不与小鼠或大鼠 IL-17A结合^[1]。
Ixekizumab (0.1-10000 pM) 以剂量依赖性方式抑制人类 IL-17A 或人类 IL-17A/F 异二聚体诱导的 HT-29 细胞生长调节致癌基因 (GRO)α 分泌。Ixekizumab 以剂量依赖性方式抑制食蟹猴 IL-17A 诱导的 HT-29 细胞 GROα 分泌^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ixekizumab (0.001-1 mg/kg；iv) 能够以剂量依赖的方式减少 C57BL/6 小鼠血浆中人 IL-17A 诱导的角质形成细胞趋化因子 (KC) 分泌^[1]。
在雄性食蟹猴中，静脉注射 1 mg/kg 后，Ixekizumab 被清除，平均半衰期为 6.5 天。在 1 mg/kg 的皮下注射；给药后，Ixekizumab 在给药后约 72 小时达到平均最大血浆浓度 11.1 μg/mL。皮下注射后的平均消除半衰期为 10.3 天^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1143503-69-8

液体

Colorless to light yellow

伊西贝单抗； 依珠奇单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. Published 2016 Apr 19.  [Content Brief]

  [2]. Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.  [Content Brief]